UNITED THERAPEUTICS CORP (UTHR) Stock Overview
USA - NASDAQ:UTHR - US91307C1027 - Common Stock
UTHR Key Statistics, Chart & Performance
The current stock price of UTHR is 418.58 USD. In the past month the price decreased by -3.25%. In the past year, price increased by 20.06%.
UTHR Latest News, Press Relases and Analysis
UTHR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About UTHR
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,305 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Company Info
UNITED THERAPEUTICS CORP
1000 Spring St
Silver Spring MARYLAND 20910 US
CEO: Martine A. Rothblatt
Employees: 1305
Phone: 13016089292
UNITED THERAPEUTICS CORP / UTHR FAQ
What does UTHR do?
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,305 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Can you provide the latest stock price for UNITED THERAPEUTICS CORP?
The current stock price of UTHR is 418.58 USD. The price decreased by -1.79% in the last trading session.
Does UTHR stock pay dividends?
UTHR does not pay a dividend.
What is the ChartMill rating of UNITED THERAPEUTICS CORP stock?
UTHR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of UNITED THERAPEUTICS CORP (UTHR)?
The PE ratio for UNITED THERAPEUTICS CORP (UTHR) is 16.34. This is based on the reported non-GAAP earnings per share of 25.62 and the current share price of 418.58 USD.
Can you provide the growth outlook for UNITED THERAPEUTICS CORP?
The Revenue of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 11.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is UNITED THERAPEUTICS CORP worth?
UNITED THERAPEUTICS CORP (UTHR) has a market capitalization of 18.93B USD. This makes UTHR a Large Cap stock.
UTHR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to UTHR. When comparing the yearly performance of all stocks, UTHR is one of the better performing stocks in the market, outperforming 85.62% of all stocks.
UTHR Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to UTHR. UTHR scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
UTHR Financial Highlights
Over the last trailing twelve months UTHR reported a non-GAAP Earnings per Share(EPS) of 25.62. The EPS increased by 17.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 40.36% | ||
| ROA | 15.71% | ||
| ROE | 17.31% | ||
| Debt/Equity | 0 |
UTHR Forecast & Estimates
22 analysts have analysed UTHR and the average price target is 489.79 USD. This implies a price increase of 17.01% is expected in the next year compared to the current price of 418.58.
For the next year, analysts expect an EPS growth of 14.09% and a revenue growth 11.6% for UTHR